These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 10175995)

  • 1. How viral load's role measures up.
    Check W
    CAP Today; 1997 Dec; 11(12):1, 14-5, 18. PubMed ID: 10175995
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination therapy for HIV disease.
    Frascino RJ
    West J Med; 1997 Nov; 167(5):346-7. PubMed ID: 9392987
    [No Abstract]   [Full Text] [Related]  

  • 3. Efavirenz in HIV infection.
    Casado JL; Moreno S
    N Engl J Med; 2000 Apr; 342(17):1290-1. PubMed ID: 10787332
    [No Abstract]   [Full Text] [Related]  

  • 4. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy.
    Jubault V; Burgard M; Le Corfec E; Costagliola D; Rouzioux C; Viard JP
    AIDS; 1998 Dec; 12(17):2358-9. PubMed ID: 9863885
    [No Abstract]   [Full Text] [Related]  

  • 5. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection.
    Fialaire P; Payan C; Vitour D; Chennebault JM; Loison J; Pichard E; Lunel F
    J Infect Dis; 1999 Aug; 180(2):574-5. PubMed ID: 10395889
    [No Abstract]   [Full Text] [Related]  

  • 6. Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy.
    Galli M; Balotta C; Meroni L; Colombo MC; Papagno L; Bagnarelli P; Testa L; Varchetta S; Colombo L; Moroni M; d'Arminio Monforte A; Clerici M; Clementi M
    AIDS; 1998 Dec; 12(18):2500-2. PubMed ID: 9875591
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials.
    Poveda E; Vispo E; Pattery T; de Mendoza C; Villacian J; Soriano V
    J Antimicrob Chemother; 2007 Dec; 60(6):1411-3. PubMed ID: 17911388
    [No Abstract]   [Full Text] [Related]  

  • 8. Choosing the best initial therapy for HIV-1 infection.
    Clumeck N
    N Engl J Med; 1999 Dec; 341(25):1925-6. PubMed ID: 10601514
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiviral update.
    PI Perspect; 1996 Nov; (No 20):8-9. PubMed ID: 11363972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects.
    Swanstrom R; Bosch RJ; Katzenstein D; Cheng H; Jiang H; Hellmann N; Haubrich R; Fiscus SA; Fletcher CV; Acosta EP; Gulick RM;
    J Infect Dis; 2004 Sep; 190(5):886-93. PubMed ID: 15295692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antiretroviral therapy in patients infected with HIV-1].
    Corti ME
    Medicina (B Aires); 1998; 58 Suppl 1():49-56. PubMed ID: 9674248
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiretroviral therapy for previously treated patients.
    Montaner JS; Mellors JW
    N Engl J Med; 2001 Aug; 345(6):452-5. PubMed ID: 11496858
    [No Abstract]   [Full Text] [Related]  

  • 13. Protease inhibitors: opium of the masses?
    Martinez LJ
    Res Initiat Treat Action; 2000 Sep; 6(3):7-11. PubMed ID: 11708167
    [No Abstract]   [Full Text] [Related]  

  • 14. Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption.
    Barreiro P; de Mendoza C; González-Lahoz J; Soriano V
    Clin Infect Dis; 2005 Sep; 41(6):897-900. PubMed ID: 16107992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-HIV agents. Saquinavir--switching from Fortovase to Invirase.
    TreatmentUpdate; 2004; 16(3):8-9. PubMed ID: 17219608
    [No Abstract]   [Full Text] [Related]  

  • 17. Four-drug regimens may be better.
    AIDS Patient Care STDS; 2000 Dec; 14(12):671. PubMed ID: 11119435
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of prior nucleoside use on the two-year virological response to an initial protease inhibitor regimen in HIV-infected patients.
    Kazanjian P; Tashima K; Hollander T; Kaul D
    HIV Clin Trials; 2001; 2(3):213-8. PubMed ID: 11590530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage therapy for patients failing their current antiretroviral regimen.
    Albrecht MA
    AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiretroviral therapy: where are we?
    Hammer SM; Yeni P
    AIDS; 1998; 12 Suppl A():S181-8. PubMed ID: 9633001
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.